<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01354340</url>
  </required_header>
  <id_info>
    <org_study_id>2011-A00145-36</org_study_id>
    <nct_id>NCT01354340</nct_id>
  </id_info>
  <brief_title>Dose Effect of Limicol on (LDL)-Cholesterol Levels</brief_title>
  <official_title>Dose Effect of Limicol on (LDL)-Cholesterol Levels in Moderate Hypercholesterolaemia</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Lescuyer Laboratory</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>BioFortis</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Lescuyer Laboratory</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The principal objective of this study is to investigate the dose-effect of the Limicol food
      supplement on LDL-cholesterol level in moderate hypercholesterolaemia subjects.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>April 2011</start_date>
  <completion_date type="Actual">January 2012</completion_date>
  <primary_completion_date type="Actual">December 2011</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Care Provider, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change from Baseline in blood LDL-cholesterol levels after 4 weeks of supplementation (limicol double dose group versus placebo group)</measure>
    <time_frame>4 weeks after baseline</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change from Baseline in blood LDL-cholesterol levels after 4 weeks of supplementation (limicol double dose group versus limicol simple dose group)</measure>
    <time_frame>4 weeks after baseline</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from Baseline in blood total cholesterol, HDL-cholesterol and TAG levels after 4 weeks of supplementation (limicol double dose group versus limicol simple dose group versus placebo group)</measure>
    <time_frame>4 weeks after baseline</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from Baseline in blood LDL-cholesterol, total cholesterol, HDL-cholesterol and TAG levels 4 weeks after end of supplementation (limicol double dose group versus limicol simple dose group versus placebo group)</measure>
    <time_frame>8 weeks after baseline</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from Baseline in CK, LDH and other safety biomarkers levels after 4 weeks of supplementation (limicol double dose group versus placebo group versus placebo group)</measure>
    <time_frame>4 weeks after baseline</time_frame>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">45</enrollment>
  <condition>Hypercholesterolaemia</condition>
  <arm_group>
    <arm_group_label>Limicol simple dose</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Limicol double doses</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Limicol</intervention_name>
    <description>3 tablets (Limicol) + 3 tablets (Placebo) / day during 1 month and follow-up 1 month without treatment</description>
    <arm_group_label>Limicol simple dose</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Limicol</intervention_name>
    <description>6 tablets (Limicol) / day during 1 month and follow-up 1 month without treatment</description>
    <arm_group_label>Limicol double doses</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>6 tablets (Placebo) / day during 1 month and follow-up 1 month without treatment</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  About 18 to 65 years (inclusive).

          -  Subject has a stable weight for at least three months before the start of the study.

          -  Subject able and willing to comply with the protocol and agreeing to give their
             consent in writing.

          -  Subject affiliated with a social security scheme.

          -  Subject willing to be included in the national register of volunteers who lend
             themselves to biomedical research.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Sebastien Peltier, PhD</last_name>
    <role>Study Director</role>
    <affiliation>Lescuyer Laboratory</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Biofortis</name>
      <address>
        <city>Nantes</city>
        <zip>44000</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>April 2012</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>May 12, 2011</study_first_submitted>
  <study_first_submitted_qc>May 13, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 16, 2011</study_first_posted>
  <last_update_submitted>April 18, 2012</last_update_submitted>
  <last_update_submitted_qc>April 18, 2012</last_update_submitted_qc>
  <last_update_posted type="Estimate">April 19, 2012</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Cholesterol</keyword>
  <keyword>LDL-cholesterol</keyword>
  <keyword>Coronary artery disease</keyword>
  <keyword>Red yeast rice</keyword>
  <keyword>Plants extract</keyword>
  <keyword>Cholesterol excess</keyword>
  <keyword>Delivery of Health Care</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hypercholesterolemia</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

